100 related articles for article (PubMed ID: 15198853)
1. LPS binding protein does not participate in the pharmacokinetics of E5564.
Kaneko K; Ueda R; Kawata T; Ishizaka S; Yoshimura T
J Endotoxin Res; 2004; 10(3):185-94. PubMed ID: 15198853
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist.
Mullarkey M; Rose JR; Bristol J; Kawata T; Kimura A; Kobayashi S; Przetak M; Chow J; Gusovsky F; Christ WJ; Rossignol DP
J Pharmacol Exp Ther; 2003 Mar; 304(3):1093-102. PubMed ID: 12604686
[TBL] [Abstract][Full Text] [Related]
3. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria.
Lamping N; Dettmer R; Schröder NW; Pfeil D; Hallatschek W; Burger R; Schumann RR
J Clin Invest; 1998 May; 101(10):2065-71. PubMed ID: 9593762
[TBL] [Abstract][Full Text] [Related]
4. Lipopolysaccharide is transferred from high-density to low-density lipoproteins by lipopolysaccharide-binding protein and phospholipid transfer protein.
Levels JH; Marquart JA; Abraham PR; van den Ende AE; Molhuizen HO; van Deventer SJ; Meijers JC
Infect Immun; 2005 Apr; 73(4):2321-6. PubMed ID: 15784577
[TBL] [Abstract][Full Text] [Related]
5. Lipopolysaccharide (LPS) binding protein catalyzes binding of LPS to lipoproteins.
Wurfel MM; Wright SD
Prog Clin Biol Res; 1995; 392():287-95. PubMed ID: 8524933
[TBL] [Abstract][Full Text] [Related]
6. Impact of sepsis-induced changes in plasma on LPS interactions with monocytes and plasma lipoproteins: roles of soluble CD14, LBP, and acute phase lipoproteins.
Kitchens RL; Thompson PA
J Endotoxin Res; 2003; 9(2):113-8. PubMed ID: 12803885
[TBL] [Abstract][Full Text] [Related]
7. Lipopolysaccharide-binding protein is required to combat a murine gram-negative bacterial infection.
Jack RS; Fan X; Bernheiden M; Rune G; Ehlers M; Weber A; Kirsch G; Mentel R; Fürll B; Freudenberg M; Schmitz G; Stelter F; Schütt C
Nature; 1997 Oct; 389(6652):742-5. PubMed ID: 9338787
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of LPS-responses by synthetic peptides derived from LBP associates with the ability of the peptides to block LBP-LPS interaction.
Araña Mde J; Vallespi MG; Chinea G; Vallespi GV; Rodriguez-Alonso I; Garay HE; Buurman WA; Reyes O
J Endotoxin Res; 2003; 9(5):281-91. PubMed ID: 14577844
[TBL] [Abstract][Full Text] [Related]
9. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia.
Lynn M; Rossignol DP; Wheeler JL; Kao RJ; Perdomo CA; Noveck R; Vargas R; D'Angelo T; Gotzkowsky S; McMahon FG
J Infect Dis; 2003 Feb; 187(4):631-9. PubMed ID: 12599080
[TBL] [Abstract][Full Text] [Related]
10. Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrations.
Wasan KM; Sivak O; Cote RA; MacInnes AI; Boulanger KD; Lynn M; Christ WJ; Hawkins LD; Rossignol DP
Antimicrob Agents Chemother; 2003 Sep; 47(9):2796-803. PubMed ID: 12936976
[TBL] [Abstract][Full Text] [Related]
11. Effects of the second-generation synthetic lipid A analogue E5564 on responses to endotoxin in [corrected] equine whole blood and monocytes.
Figueiredo MD; Moore JN; Vandenplas ML; Sun WC; Murray TF
Am J Vet Res; 2008 Jun; 69(6):796-803. PubMed ID: 18518661
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of E5564, a lipopolysaccharide antagonist, in patients with impaired hepatic function.
Liang E; Wong YN; Allen I; Kao R; Marino M; DiLea C
J Clin Pharmacol; 2003 Dec; 43(12):1361-9. PubMed ID: 14615472
[TBL] [Abstract][Full Text] [Related]
13. Lipopolysaccharide-binding protein down-regulates the expression of interleukin-6 by human gingival fibroblast.
Ren L; Leung WK; Loo TW; Jin L
J Periodontal Res; 2005 Oct; 40(5):407-16. PubMed ID: 16105094
[TBL] [Abstract][Full Text] [Related]
14. Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue.
Rossignol DP; Lynn M
J Endotoxin Res; 2002; 8(6):483-8. PubMed ID: 12697095
[TBL] [Abstract][Full Text] [Related]
15. Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers.
Rossignol DP; Wasan KM; Choo E; Yau E; Wong N; Rose J; Moran J; Lynn M
Antimicrob Agents Chemother; 2004 Sep; 48(9):3233-40. PubMed ID: 15328078
[TBL] [Abstract][Full Text] [Related]
16. Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers.
Rossignol DP; Wong N; Noveck R; Lynn M
Innate Immun; 2008 Dec; 14(6):383-94. PubMed ID: 19039062
[TBL] [Abstract][Full Text] [Related]
17. Lipopolysaccharide-binding protein modulates hepatic damage and the inflammatory response after hemorrhagic shock and resuscitation.
Lehnert M; Uehara T; Bradford BU; Lind H; Zhong Z; Brenner DA; Marzi I; Lemasters JJ
Am J Physiol Gastrointest Liver Physiol; 2006 Sep; 291(3):G456-63. PubMed ID: 16614372
[TBL] [Abstract][Full Text] [Related]
18. Interaction between lipopolysaccharide (LPS), LPS-binding protein (LBP), and planar membranes.
Gutsmann T; Haberer N; Carroll SF; Seydel U; Wiese A
Biol Chem; 2001 Mar; 382(3):425-34. PubMed ID: 11347890
[TBL] [Abstract][Full Text] [Related]
19. LPS binding protein is important in the airway response to inhaled endotoxin.
Brass DM; Savov JD; Whitehead GS; Maxwell AB; Schwartz DA
J Allergy Clin Immunol; 2004 Sep; 114(3):586-92. PubMed ID: 15356561
[TBL] [Abstract][Full Text] [Related]
20. Lipopolysaccharide binding protein-deficient mice have a normal defense against pulmonary mycobacterial infection.
Branger J; Leemans JC; Florquin S; Speelman P; Golenbock DT; van der Poll T
Clin Immunol; 2005 Aug; 116(2):174-81. PubMed ID: 15993364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
